팝업레이어 알림


 

PREV

NEXT

Deciphering (Aging) &
Beyond (Longevity)

We CRAVE longevity with dignity

Novel Insights into MicroRNAs
and Senescence

Innovative Gene therapy
for Neurological Diseases

Business

VIRAL VECTOR CDMO

Viral vector-specific CDMO based on virus production/purification capabilities

Business

Gene Therapy of ANLBIO

Gene therapy for neurodegenerative diseases targeting microRNA and others

Business

AAV Delivery Platform of ANLBIO

gene therapy modalities with an innovative delivery platform of viral vectors including AAV

PIPELINE

Candidate Indication Development status
  • Research
  • Lead Optimization
  • In Vitro
  • In Vivo
  • Phase Ⅰ
  • Phase Ⅱ
  • Phase Ⅲ
  • FDA
  • Commercialization
miR - based Gene Therapy ANL-101 Alzheimer´s Disease
In Vivo
ANL-102 MCI
Lead Optimization
ANL-103 Parkinson´s Disease
Lead Optimization
Monogenic gene therapy ANL-301 Undisclosed
In Vitro
ANL-302 Undisclosed
Lead Optimization
ANL-303 Undisclosed
Research

좌우로 스크롤 하시면 전체 내용을 확인할 수 있습니다.

PARTNER

  • Partner
  • Investment
  • Biovian

  • Naason Science

  • MedySapiens

  • SOONCHUNHYANG UNIVERSITY

NOTICE

VIEW MORE

NEWS

VIEW MORE

TOP